Study of the Effect of EECP on Subclinical Atherosclerosis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HMG-CoA reductase inhibitors (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Acronyms SESA
Most Recent Events
- 02 Nov 2020 Biomarkers information updated
- 26 Dec 2012 Planned end date changed from 1 Apr 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 21 May 2012 Trial phase changed from II to I as reported by Chinese Clinical Trial Register record.